MedPath
Found 13 clinical trials|View Analysis
Sort by:

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2
Recruiting
Conditions
Thyroid Gland Oncocytic Carcinoma
Thyroid Gland Papillary Carcinoma
Thyroid Gland Follicular Carcinoma
Interventions
Procedure: Biospecimen Collection
Drug: Cobimetinib
Procedure: Computed Tomography
Procedure: Diagnostic Imaging
Procedure: I-131 Uptake Test
Radiation: Iodine I-131
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Biological: Recombinant Thyrotropin Alfa
Procedure: Ultrasound Imaging
Drug: Vemurafenib
First Posted Date
2024-06-04
Last Posted Date
2024-12-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
21
Registration Number
NCT06440850
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

First Posted Date
2021-01-25
Last Posted Date
2024-02-01
Lead Sponsor
Fondazione Melanoma Onlus
Target Recruit Count
95
Registration Number
NCT04722575
Locations
🇮🇹

Ospedale S.M. Annunziata - Azienda USL Toscana Centro, Bagno A Ripoli, Firenze, Italy

🇮🇹

IRCCS San Martino - IST, Genova, Italy

🇮🇹

Fondazione I.R.C.C.S. Istituto Nazionale dei Tumori, Milano, Italy

and more 3 locations

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Phase 2
Active, not recruiting
Conditions
BRAF V600E Mutation Present
Papillary Craniopharyngioma
Interventions
Drug: Vemurafenib
Drug: Cobimetinib
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
First Posted Date
2017-07-21
Last Posted Date
2024-05-23
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
24
Registration Number
NCT03224767
Locations
🇺🇸

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States

🇺🇸

Sutter Roseville Medical Center, Roseville, California, United States

🇺🇸

Eden Hospital Medical Center, Castro Valley, California, United States

and more 103 locations

ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma

Phase 2
Withdrawn
Conditions
Stage IIIB-C Melanoma
Interventions
First Posted Date
2016-12-29
Last Posted Date
2018-05-09
Lead Sponsor
Inova Health Care Services
Registration Number
NCT03005639
Locations
🇺🇸

Inova Schar Cancer Institute, Fairfax, Virginia, United States

Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

Phase 2
Conditions
Melanoma, Malignant, of Soft Parts
Interventions
First Posted Date
2016-11-18
Last Posted Date
2020-06-05
Lead Sponsor
Radboud University Medical Center
Target Recruit Count
200
Registration Number
NCT02968303
Locations
🇳🇱

UMC Utrecht, Utrecht, Netherlands

🇳🇱

The Netherlands Cancer Institute, Amsterdam, Netherlands

🇳🇱

Radboudumc, Nijmegen, Netherlands

and more 10 locations

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Phase 1
Terminated
Conditions
Melanoma
Interventions
First Posted Date
2016-06-29
Last Posted Date
2022-01-03
Lead Sponsor
Yana Najjar
Target Recruit Count
9
Registration Number
NCT02818023
Locations
🇺🇸

UPMC Cancer Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

First Posted Date
2016-02-26
Last Posted Date
2024-12-27
Lead Sponsor
American Society of Clinical Oncology
Target Recruit Count
3791
Registration Number
NCT02693535
Locations
🇺🇸

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States

🇺🇸

Sutter Auburn, Auburn, California, United States

and more 125 locations

Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma

Phase 2
Completed
Conditions
Melanoma
Interventions
First Posted Date
2015-10-22
Last Posted Date
2020-02-17
Lead Sponsor
Grupo Español Multidisciplinar de Melanoma
Target Recruit Count
70
Registration Number
NCT02583516
Locations
🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

🇪🇸

Hospital Universitario de Canarias, Tenerife, Spain

🇪🇸

Hospital Clínico Universitario de Salamanca, Salamanca, Spain

and more 15 locations

Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis

Phase 2
Completed
Conditions
Malignant Melanoma
Interventions
First Posted Date
2015-09-01
Last Posted Date
2020-01-27
Lead Sponsor
Center Eugene Marquis
Target Recruit Count
43
Registration Number
NCT02537600
Locations
🇫🇷

CHU de Bordeaux, Bordeaux, France

🇫🇷

CHU Caen - Hôpital Clémenceau, Caen, France

🇫🇷

CHU Ambroise Paré, Boulogne, France

and more 14 locations
© Copyright 2025. All Rights Reserved by MedPath